涎腺腺样囊性癌组织色素框同源蛋白2、T细胞免疫球蛋白黏液素3表达水平及与患者临床病理特征、预后的关系

doi:10.3969/j.issn.1006-5725.2025.12.015

Abstract

Abstract:

Objective To investigate CBX2 and TIM3 in salivary adenoid cystic carcinoma （SACC） tissue and their relationship with clinical pathological features and prognosis. Methods 80 patients with SACC who underwent surgical treatment in the First Affiliated Hospital of Hebei North University from January 2016 to January 2020 were selected. Immunohistochemistry was used to measure CBX2 and TIM3 in tissues. The relationship between CBX2 and TIM3 in SACC tissue and prognosis was discussed though Kaplan-Meier method. The factors influencing the prognosis of SACC were discussed using multivariate Cox regression. Results The positive rates of CBX2 and TIM3 in SACC tissues were clearly higher than those in normal glandular tissues adjacent to cancer （χ² = 11.237， 8.229， P < 0.05）. The CBX2 and TIM3 were associated with nerve invasion and distant metastasis （P < 0.05）. After a 5-year follow-up， 26 cases died and 54 cases survived， with an overall 5-year survival rate of 67.50% （54/80）. The death group had higher positive rates of CBX2 and TIM3 in SACC tissues than the survival group （P < 0.05）. Patients with positive CBX2 and TIM3 in SACC tissues had clearly lower 5-year survival rate than patients with negative CBX2 and TIM3 （Log Rank χ² = 6.564， 5.197， P < 0.05）. CBX2， TIM3 positivity， nerve invasion， and distant metastasis were risk factors affecting prognosis （P < 0.05）. Conclusion The positive expression of CBX2 and TIM3 in SACC tissues is closely related to the clinical pathological features and prognosis of patients.

Key words: salivary adenoid cystic carcinoma, CBX2, TIM3, clinical pathological features, prognosis

CLC Number:

R781.7

Xuan ZHANG,Zhenli LIU,Yongchao YANG,Sai MA,Bo LIU,Hongjuan LYU. The levels of CBX2 and TIM3 in salivary adenoid cystic carcinoma tissue and their relationship with clinical pathological features and prognosis[J]. The Journal of Practical Medicine, 2025, 41(12): 1873-1878.

Figures/Tables 7

Fig. 1

Tab.1

Tab.2

Tab.3

Fig. 2

Fig. 3

Tab.4

References 25

1	SALEH E， UKWAS A. Adenoid Cystic Carcinoma of Salivary Glands： A Ten-Year Review and an Assessment of the Current Management， Surgery， Radiotherapy， and Chemotherapy［J］. Int J Otolaryngol， 2023，2023（1）：1-8. doi:10.1155/2023/7401458 doi: 10.1155/2023/7401458
2	CANTÙ G. Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A： From aetiopathogenesis to diagnosis［J］. Acta Otorhinolaryngol Ital， 2021，41（3）：206-214. doi:10.14639/0392-100x-n1379 doi: 10.14639/0392-100x-n1379
3	CHOWSILPA S， AN D， MALEKI Z. Adenoid cystic carcinoma cytology： Salivary gland and nonsalivary gland［J］. Diagn Cytopathol， 2020，48（12）：1282-1289. doi:10.1002/dc.24573 doi: 10.1002/dc.24573
4	LIU X， YANG X， ZHAN C， et al. Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands： Where We Are and Where We Need to Go［J］. Front Oncol， 2020，10（1）：1-13. doi:10.3389/fonc.2020.01493 doi: 10.3389/fonc.2020.01493
5	FANG Y， PENG Z， WANG Y， et al. Current opinions on diagnosis and treatment of adenoid cystic carcinoma［J］. Oral Oncol， 2022，130（1）：1-15. doi:10.1016/j.oraloncology.2022.105945 doi: 10.1016/j.oraloncology.2022.105945
6	MICHAELIDES I， KÜNZEL J， ETTL T， et al. Adenoid cystic carcinoma of the salivary glands： A pilot study of potential therapeutic targets and characterization of the immunological tumor environment and angiogenesis［J］. Eur Arch Otorhinolaryngol， 2023，280（6）：2937-2944. doi:10.1007/s00405-023-07884-3 doi: 10.1007/s00405-023-07884-3
7	XU X， LAI C， LUO J， et al. The predictive significance of chromobox family members in prostate cancer in humans［J］. Cell Oncol （Dordr）， 2024，47（4）：1315-1331. doi:10.1007/s13402-024-00929-7 doi: 10.1007/s13402-024-00929-7
8	PENG L， HUANG X， QING D， et al. MiR-30a-5p inhibits cell behaviors in esophageal cancer via modulating CBX2［J］. Mutat Res， 2023，826（1）：1-11. doi:10.1016/j.mrfmmm.2023.111818 doi: 10.1016/j.mrfmmm.2023.111818
9	LU C， TAN Y. Promising immunotherapy targets： TIM3， LAG3， and TIGIT joined the party［J］. Mol Ther Oncol， 2024，32（1）：2-13. doi:10.1016/j.omton.2024.200773 doi: 10.1016/j.omton.2024.200773
10	PALACIOS LM， PEYRET V， VIANO ME， et al. TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages： An Emerging Immunotherapeutic Target［J］. Biology （Basel）， 2022，11（11）：1-13. doi:10.3390/biology11111609 doi: 10.3390/biology11111609
11	BAYAT P， MAHDAVI N， YOUNESPOUR S， et al. Interactive role of miR-29， miR-93， miR-205， and VEGF in salivary adenoid cystic carcinoma［J］. Clin Exp Dent Res， 2023，9（1）：112-121. doi:10.1002/cre2.678 doi: 10.1002/cre2.678
12	WANG J， YANG B， ZHANG X， et al. Chromobox proteins in cancer： Multifaceted functions and strategies for modulation （Review）［J］. Int J Oncol， 2023，62（3）：1-12. doi:10.3892/ijo.2023.5484 doi: 10.3892/ijo.2023.5484
13	HU CY， LI X， ZENG T， et al. Significance of chromobox protein （CBX） expression in diffuse LBCL［J］. Gene， 2022，813（1）：1-12. doi:10.1016/j.gene.2021.146092 doi: 10.1016/j.gene.2021.146092
14	SUN R， TU X， CHAN S， et al. CBX2 Deletion Suppresses Growth and Metastasis of Colorectal Cancer by Mettl3-p38/ERK MAPK Signalling Pathway［J］. J Cancer， 2024，15（8）：2123-2136. doi:10.7150/jca.92633 doi: 10.7150/jca.92633
15	ZHU J， LUO J E， CHEN Y， et al. Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer［J］. J Ovarian Res， 2021，14（1）：1-13. doi:10.1186/s13048-021-00888-9 doi: 10.1186/s13048-021-00888-9
16	ZENG M， LI B， YANG L， et al. CBX2 depletion inhibits the proliferation， invasion and migration of gastric cancer cells by inactivating the YAP/β-catenin pathway［J］. Mol Med Rep， 2021，23（2）：137-146. doi:10.3892/mmr.2020.11776 doi: 10.3892/mmr.2020.11776
17	LI W， SHI R， GAO Y， et al. CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness［J］. J Biol Chem， 2025，301（2）：1-10. doi:10.1016/j.jbc.2025.108170 doi: 10.1016/j.jbc.2025.108170
18	朱元媛，闫洪超，刘永利，等. BTLA、LAG3和TIM3在上皮性卵巢癌组织中的表达意义［J］. 实用医学杂志，2019，35（5）：698-702.
19	ZHAO L， CHENG S， FAN L， et al. TIM-3： An update on immunotherapy［J］. Int Immunopharmacol， 2021，99（1）：1-13. doi:10.1016/j.intimp.2021.107933 doi: 10.1016/j.intimp.2021.107933
20	KANDEL S， ADHIKARY P， LI G， et al. The TIM3/Gal9 signaling pathway： An emerging target for cancer immunotherapy［J］. Cancer Lett， 2021，510（1）：67-78. doi:10.1016/j.canlet.2021.04.011 doi: 10.1016/j.canlet.2021.04.011
21	SAUER N， JANICKA N， SZLASA W， et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors［J］. Cancer Immunol Immunother， 2023，72（11）：3405-3425. doi:10.1007/s00262-023-03516-1 doi: 10.1007/s00262-023-03516-1
22	YANG R， SUN L， LI C F，et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy［J］. Nat Commun， 2021，12（1）：832-845. doi:10.1038/s41467-021-21099-2 doi: 10.1038/s41467-021-21099-2
23	GARDNER A， DE MINGO PULIDO Á， HÄNGGI K， et al. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization［J］. J Immunother Cancer， 2022，10（1）：1-11. doi:10.1136/jitc-2021-003571 doi: 10.1136/jitc-2021-003571
24	王辉，张利娟，杨芳. 半乳糖凝集素-9和T细胞免疫球蛋白黏蛋白分子3在口腔扁平苔藓和口腔鳞状细胞癌组织中的表达及临床意义［J］. 癌症进展，2020，18（6）：576-579.
25	田绣云，周美云，韩瑞，等. 涎腺腺样囊性癌的临床特征及预后分析［J］. 医学研究杂志，2023，52（6）：108-111，116.

项目	例数	CBX2		TIM3
项目	例数	阳性	阴性	阳性	阴性
SACC组织	80	45（56.25）	35（43.75）	44（55.00）	36（45.00）
癌旁正常腺体组织	80	24（30.00）	56（70.00）	26（32.50）	54（67.50）
χ² 值	-	11.237		8.229
P值	-	< 0.001		0.004

病理参数	例数	CBX2		χ² 值	P值	TIM3		χ² 值	P值
病理参数	例数	阳性（n = 45）	阴性（n = 35）	χ² 值	P值	阳性（n = 44）	阴性（n = 36）	χ² 值	P值
年龄				0.080	0.778			0.245	0.621
< 60岁	42	23（51.11）	19（54.29）			22（50.00）	20（55.56）
≥ 60岁	38	22（48.89）	16（45.71）			22（50.00）	16（44.44）
性别				0.135	0.713			1.122	0.289
男	37	20（44.44）	17（48.57）			18（40.91）	19（52.78）
女	43	25（55.56）	18（51.43）			26（59.09）	17（47.22）
临床分期				1.175	0.278			0.831	0.362
Ⅰ~Ⅱ期	51	31（68.89）	20（57.14）			30（68.18）	21（58.33）
Ⅲ~Ⅳ期	29	14（31.11）	15（42.86）			14（31.82）	15（41.67）
淋巴结转移				0.888	0.346			0.367	0.544
是	25	16（35.56）	9（25.71）			15（34.09）	10（27.78）
否	55	29（64.44）	26（74.29）			29（65.91）	26（72.22）
神经侵犯				7.798	0.005			4.565	0.033
有	34	13（28.89）	21（60.00）			14（31.82）	20（55.56）
无	46	32（71.11）	14（40.00）			30（68.18）	16（44.44）
远处转移				5.038	0.025			6.474	0.011
有	28	11（24.44）	17（48.57）			10（22.73）	18（50.00）
无	52	34（75.56）	18（51.43）			34（77.27）	18（50.00）
组织学分型				1.261	0.532			2.850	0.241
腺样型	34	18（40.00）	16（45.71）			15（34.09）	19（52.78）
管状型	25	13（28.89）	12（34..29）			16（36.36）	9（25.00）
实体型	21	14（31.11）	7（20.00）			13（29.55）	8（22.22）
肿瘤部位				1.315	0.251			1.046	0.307
大唾液腺	62	37（82.22）	25（71.43）			36（81.82）	26（72.22）
小唾液腺	18	8（17.78）	10（28.57）			8（18.18）	10（27.78）

预后	例数	CBX2阳性	TIM3阳性
死亡组	26	23（88.46）	21（80.77）
存活组	54	22（40.74）	23（42.59）
χ ² 值		16.240	10.335
P值		< 0.001	0.001

影响因素	单因素分析			多因素分析
影响因素	HR	95%CI	P值	HR	95%CI	P值
CBX2	2.642	1.392 ~ 5.015	0.003	3.064	1.545 ~ 4.166	< 0.001
TIM3	2.167	1.218 ~ 3.856	0.009	2.315	1.535 ~ 3.870	< 0.001
神经侵犯	1.675	1.161 ~ 2.417	0.006	1.697	1.297 ~ 3.001	0.007
远处转移	1.944	1.276 ~ 2.963	0.002	1.483	1.296 ~ 3.283	0.009

[1]	Yingdao CHEN,Haining LI,Yuying LI,Qiping ZHANG,Bingsong LIANG,Guohui. LI. The predictive value of serum miR-143-3p and miR-188-5p levels for poor prognosis in patients with acute cerebral infarction after thrombolysis [J]. The Journal of Practical Medicine, 2025, 41(8): 1117-1122.
[2]	Juan SHEN,Yong WANG,Qiuping WANG,Chen. LING. Relationship between the immune status of patients with multiple myeloma and the changes in the levels of detection of peripheral blood RDW-SD， sBCMA， sFLCR and prognosis [J]. The Journal of Practical Medicine, 2025, 41(8): 1161-1166.
[3]	Yin GUO,Haiqing REN,Xiaoyang GUO,Jianghua ZUO,Ting. WANG. Study on the correlation between serum APRIL， PLA2R⁃Ab， and 25⁃（OH） D₃ levels and the severity and prognosis of primary membranous nephropathy [J]. The Journal of Practical Medicine, 2025, 41(8): 1199-1204.
[4]	Weixiang FENG,Juan WANG,Yanbin SONG,Sheliang XUE,Wenhua LI. The long⁃term prognosis of nonparoxysmal atrial fibrillation （NPAF） patients after radiofrequency catheter ablation [J]. The Journal of Practical Medicine, 2025, 41(7): 1036-1043.
[5]	Fuxia ZHENG,Lijun MIAO,Fengxiang HUANG,Shifu HUANG,Zengyan GAO,Ruixia ZHANG,Yong MENG. The correlation between the levels of APC， TXB2， and sB7⁃H3 in peripheral blood of elderly patients with pneumonia and the severity and prognosis of the disease [J]. The Journal of Practical Medicine, 2025, 41(7): 1056-1061.
[6]	Chunmei MA,Zhikang WU,Ke CHEN,Ziyan WANG,Yu WANG,Lian WANG. Effect of pulmonary artery to aorta diameter ratio on prognosis in patients with acute decompensated heart failure [J]. The Journal of Practical Medicine, 2025, 41(7): 960-967.
[7]	Tong DUAN,Qi WU,Hui. LIU. Correlation between iron death⁃related gene expression level and myocardial dysfunction and prognosis in sepsis [J]. The Journal of Practical Medicine, 2025, 41(6): 846-851.
[8]	Zhuolin YAO,Zhen LI,Caihua ZHANG,Mingmei ZHANG,Ruolin JIA,Yuan CAO,Yiping WANG,Yichun. GUAN. Analysis of clinical outcome of IVF/ICSI with dual⁃stimulation protocol in POSEIDON patients with low expected prognosis [J]. The Journal of Practical Medicine, 2025, 41(4): 580-588.
[9]	Shenglei ZHANG,Ruicong TIAN,Jingjing JIN,Fan LU,Meijuan CHENG,Yaling BAI,Jinsheng. XU. To study the relationship between lymphocyte subsets and renal clinicopathological features and prognosis in patients with IgA nephropathy [J]. The Journal of Practical Medicine, 2025, 41(3): 352-357.
[10]	Yiyang ZHAI,Yunyi MA,Junying ZHAI,Hongli NIU,Ying. WANG. The relationship between tumor necrosis factor alpha inducible protein 8 family members 2， cell proliferation nuclear antigen expression levels， and clinical pathological parameters and prognosis in endometrial cancer tissue [J]. The Journal of Practical Medicine, 2025, 41(3): 379-384.
[11]	Danping WANG,Yufeng CAI,Dehua HU,Liang. ZHANG. The role of LncRNA RMST in gastric cancer： Expression levels， diagnostic value， and prognostic implicationssion [J]. The Journal of Practical Medicine, 2025, 41(3): 409-413.
[12]	Yujian CUI,Yuke LI,Sainan ZHU,Shuangling LI,Nan. LI. The association between early peripheral perfusion and acute kidney injury in patients admitted to the intensive care unit following major noncardiac surgery [J]. The Journal of Practical Medicine, 2025, 41(2): 195-201.
[13]	Jinlan GUO,Xiaoning ZHANG,Jiahui JIANG,Tao. YUAN. Expression of ACTN1 in cutaneous squamous cell carcinoma and its correlation with clinicopathological features and prognosis [J]. The Journal of Practical Medicine, 2025, 41(2): 232-237.
[14]	Ke XU,Mingzhe ZHANG,Mingyang WANG,Song. LIU. Correlation between plasma ADAMTS13 level， disease severity and prognosis in patients with endometriosis [J]. The Journal of Practical Medicine, 2025, 41(2): 238-243.
[15]	Kui YANG,Xuran PAN,Min. SHAO. Effects of glucocorticoid on APACHE Ⅱ， SOFA scores and prognosis of elderly patients with severe pneumonia and respiratory failure [J]. The Journal of Practical Medicine, 2025, 41(10): 1569-1574.

The levels of CBX2 and TIM3 in salivary adenoid cystic carcinoma tissue and their relationship with clinical pathological features and prognosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 25

Related Articles 15

Recommended Articles

Metrics

Comments